Neurofilament proteins have been validated as specific body fluid biomarkers of neuro-
axonal injury. The advent of highly sensitive analytical platforms that enable reliable …

Clinical, pathological, and imaging evidence in multiple sclerosis (MS) suggests that a
smoldering inflammatory activity is present from the earliest stages of the disease and …

One of the biggest challenges in managing multiple sclerosis is the heterogeneity of clinical
manifestations and progression trajectories. It still remains to be elucidated whether this …

While neurodegeneration underlies the pathological basis for permanent disability in
multiple sclerosis (MS), predictive biomarkers for progression are lacking. Using an animal …

Multiple Sclerosis Journal 00 (0) 2 journals. sagepub. com/home/msj baseline z-score
performed better than absolute NfL values in identifying cases with clinical/MRI activity …

Understanding multiple sclerosis as a disease spectrum: abov... : Current Opinion in Neurology
Understanding multiple sclerosis as a disease spectrum: above and below the clinical …

Objective Progression prediction is a significant unmet need in people with progressive
multiple sclerosis (pwPMS). Studies on glial fibrillary acidic protein (GFAP) have either been …

Background Definitions of aggressive MS employ clinical and MR imaging criteria to identify
highly active, rapidly progressing disease courses. However, the degree of overlap between …

Background Progression independent of relapse activity (PIRA) has been described since
the early stage of relapsing multiple sclerosis (RMS). However, little is known about the …

Introduction Body fluid markers could be helpful to predict the conversion into clinically
definite multiple sclerosis (MS) in people with a first demyelinating event of the central …